Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Eyenovia Shares Dip Despite FDA Approving Its First Product

Published 08/05/2023, 19:39
Updated 08/05/2023, 20:40
© Reuters.  Eyenovia Shares Dip Despite FDA Approving Its First Product
EYEN
-

Benzinga - The FDA approved Eyenovia Inc's (NASDAQ: EYEN) Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired.

The approval marks the first product using Eyenovia's proprietary Optejet device to be approved by any regulatory authority.

Also Read: Eyenovia's Optejet Shows Lower Proinflammatory Cytokines Levels, Chemokines Than Standard Drops.

Mydcombi is designed to improve the efficiency of the estimated 106 million office-based comprehensive eye exams performed every year in the United States and the estimated 4 million pharmacologic mydriasis applications for cataract surgery.

The product is contraindicated and should not be used in patients with known hypersensitivity to any formulation component.

"We look forward to introducing Mydcombi to key offices beginning this summer while we bring our internal manufacturing capabilities online for 2024," stated Michael Rowe, CEO.

The approval comes with warnings, including significant elevations in blood pressure and rare central nervous system disturbances in pediatric patients.

The drug can also produce transient elevation of intraocular pressure and rebound miosis (excessive pupil shrinking) after one day of administration.

Price Action: EYEN shares are down 1.63% at $4.53 on the last check Monday.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.